Nanologica Expands Launch Road Show after Good Reception

After a successful first activity of the global launch of the company's silica for preparative chromatography, NLAB Saga®, Nanologica expands the road show with participation at additional chromatography conferences.

The launch of Nanologica’s silica for preparative chromatography started at the Purify'22 Chromatography Purification Conclave on April 7 in Hyderabad, India, where the products received a very good reception. In light of this, Nanologica has expanded its road show with additional conferences for chromatography. The company plans to attend the following conferences in 2022:

We have recently returned from a very successful first conference in Hyderabad, India. It is fantastic to once again be able to travel and meet customers, and to present NLAB Saga® that we believe will contribute to great cost savings for peptide manufacturing companies. After many manufacturers having helped with the development of Covid-19 vaccines during the pandemic, we now see a very large activity around the development of peptides. The interest in our products is greater than expected and we are very much looking forward to the continued launch”, Nanologica’s CEO Andreas Bhagwani comments.

An updated conference schedule is found in Nanologica’s calendar on the company website.


To schedule a meeting or receive further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail:


About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Drug Development, Nanologica provides a unique drug delivery platform for local delivery of drugs to the lung with the aim of providing new treatment options for patients with lung diseases.  In Chromatography, the company aims to make insulin available to more patients in need, by lowering the cost of manufacturing. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed on Nasdaq Stockholm since March 29, 2022. For further information, please visit